Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

324 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Guselkumab effectiveness and survival in patients with psoriasis and psoriatic arthritis: Multicenter analysis in daily clinical practice by the Spanish Psoriasis Group.
Rocamora V, Crespi L, Ferran M, Llamas-Velasco M, Del Alcázar E, Carrascosa JM, Beltran E, Urruticoechea-Arana A, Estebaranz JLL, Vidal D, Riera J, Rodríguez L, Armesto S, Fernández JM, Aparicio G, Pérez S, Porcar S, Montesinos E, Gallardo F. Rocamora V, et al. Among authors: carrascosa jm. Dermatol Ther. 2022 Nov;35(11):e15865. doi: 10.1111/dth.15865. Epub 2022 Oct 9. Dermatol Ther. 2022. PMID: 36175141
[Adverse reactions during biological therapy for psoriasis: results of a survey of the Spanish Psoriasis Group].
Sánchez-Regaña M, Dilmé E, Puig L, Bordas X, Carrascosa JM, Ferran M, Herranz P, García-Bustinduy M, López Estebaranz JL, Alsina M, Rodríguez MA, Ribera M, Fernández-López E, Moreno JC, Belinchón Romero I, Vidal D; Grupo Español de Psoriasis de la Academia Española. Sánchez-Regaña M, et al. Among authors: carrascosa jm. Actas Dermosifiliogr. 2010 Mar;101(2):156-63. Actas Dermosifiliogr. 2010. PMID: 20223158 Spanish.
[Narrowband UV-B, monochromatic excimer laser, and photodynamic therapy in psoriasis: a consensus statement of the Spanish Psoriasis Group].
Carrascosa JM, López-Estebaranz JL, Carretero G, Daudén E, Ferrándiz C, Vidal D, Belinchón I, Sánchez-Regaña M, Puig L; Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología. Carrascosa JM, et al. Actas Dermosifiliogr. 2011 Apr;102(3):175-86. doi: 10.1016/j.ad.2010.11.002. Actas Dermosifiliogr. 2011. PMID: 21310368 Free article. Spanish.
[Clinical characteristics and disease course in patients treated with efalizumab following suspension of marketing authorization by the European medicines agency: a multicenter observational study].
Morell L, Carrascosa JM, Ferrándiz C, García-Bustinduy M, Fonseca E, Carretero G, Daudén E, Marrón SE, López-Estebaranz JL, Ferrán M, Sánchez-Regaña M, Muñoz-Santos C, Belinchón I, Puig L; Grupo Español de Psoriasis. Morell L, et al. Among authors: carrascosa jm. Actas Dermosifiliogr. 2011 Jun;102(5):354-64. doi: 10.1016/j.ad.2010.12.013. Epub 2011 Apr 29. Actas Dermosifiliogr. 2011. PMID: 21530928 Free article. Spanish.
Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting.
Navarro R, Vilarrasa E, Herranz P, Puig L, Bordas X, Carrascosa JM, Taberner R, Ferrán M, García-Bustinduy M, Romero-Maté A, Pedragosa R, García-Diez A, Daudén E. Navarro R, et al. Among authors: carrascosa jm. Br J Dermatol. 2013 Mar;168(3):609-16. doi: 10.1111/bjd.12045. Br J Dermatol. 2013. PMID: 22985451
Use of off-label doses is frequent in biologic therapy for moderate to severe psoriasis: A cross-sectional study in clinical practice.
Carrascosa JM, Garcia-Doval I, Pérez-Zafrilla B, Carretero G, Vanaclocha F, Daudén E, De la Cueva-Dobao P, Belinchón I, Alsina M, López-Estebaranz JL, Ferrán M, Torrado R, Rivera R, Carazo C, Barboza L, Ferrándiz C; BIOBADADERM Study Group. Carrascosa JM, et al. J Dermatolog Treat. 2015;26(6):502-6. doi: 10.3109/09546634.2015.1034070. Epub 2015 Apr 17. J Dermatolog Treat. 2015. PMID: 25886087
Does the treatment ladder for systemic therapy in moderate to severe psoriasis only go up? The percentage of patients with severe psoriasis on biologics increases over time.
Carrascosa JM, Rivera N, Garcia-Doval I, Carretero G, Vanaclocha F, Daudén E, Gómez-García FJ, De-la-Cueva-Dobao P, Herrera-Ceballos E, Belinchón I, Alsina M, Sánchez-Carazo JL, Ferrán M, Lopez-Estebaranz JL, Pérez-Zafrilla B, Llamas M, Rivera R, Ferrándiz C; BIOBADADERM Study Group. Carrascosa JM, et al. Actas Dermosifiliogr. 2015 Oct;106(8):638-43. doi: 10.1016/j.ad.2015.04.013. Epub 2015 Jun 30. Actas Dermosifiliogr. 2015. PMID: 26141003 Free article. English, Spanish.
Development of clinical prediction models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based on the BIOBADADERM cohort.
García-Doval I, Pérez-Zafrilla B, Ferrandiz C, Carretero G, Daudén E, de la Cueva P, Gómez-García FJ, Herrera-Ceballos E, Belinchón-Romero I, Sánchez-Carazo JL, López-Estebaranz JL, Alsina M, Ferrán M, Torrado R, Carrascosa JM, Rivera R, Vanaclocha F; BIOBADADERM Study Group. García-Doval I, et al. Among authors: carrascosa jm. J Dermatolog Treat. 2016;27(3):203-9. doi: 10.3109/09546634.2015.1088130. Epub 2015 Sep 25. J Dermatolog Treat. 2016. PMID: 26367799
324 results